NOVAGEN HOLDING CORP has a total of 60 patent applications. Its first patent ever was published in 2006. It filed its patents most often in United States, China and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are KIRIN-AMGEN INC, NEURONAX and SERPIN PHARMA LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | China | 5 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | Hong Kong | 4 | |
#5 | Japan | 4 | |
#6 | Republic of Korea | 4 | |
#7 | Brazil | 3 | |
#8 | Canada | 3 | |
#9 | Taiwan | 3 | |
#10 | WIPO (World Intellectual Property Organization) | 3 | |
#11 | Australia | 2 | |
#12 | Israel | 2 | |
#13 | Mexico | 2 | |
#14 | Malaysia | 2 | |
#15 | New Zealand | 2 | |
#16 | Singapore | 2 | |
#17 | South Africa | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Zhang Rui | 53 |
#2 | Wang Haitao | 52 |
#3 | Xu Jing | 52 |
#4 | Liu Longbin | 51 |
#5 | Du Yong | 50 |
#6 | Li Jizhi | 26 |
#7 | Wang Ling | 26 |
#8 | Mao Chunsheng | 25 |
#9 | Yong Du | 8 |
#10 | Jing Xu | 6 |
Publication | Filing date | Title |
---|---|---|
MY157907A | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo | |
TW201516058A | Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo | |
US2008312148A1 | Recombinant human interferon-like proteins | |
US2007178112A1 | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |